Please assess the completion status of the following clinical trial:

Trial Title: Phase II Front-line Ponatinib in Adult Philadelphia+/BCR-ABL+ Acute Lymphoblastic Leukemia.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. To be classified as having Ph+ ALL, patients must have \>20% blasts in bone marrow at the time of diagnosis and no prior history of CML.~2. Patients with previously untreated Ph+ and/or BCR/ABL + ALL:~   * age ≥ 60 years old or~  * age ≥ 18 years old, but unfit for program of intensive therapy and allogeneic SCT~3. Adequate hepatic function as defined by the following criteria:~   * total serum bilirubin ≤1.5 x upper limit of normal (ULN), unless due to Gilbert's syndrome~  * alanine aminotransferase (ALT) ≤2.5 × ULN~  * aspartate aminotransferase (AST) ≤2.5 × ULN.~4. Adequate pancreatic function as defined by the following criterion:~   - serum lipase and amylase ≤1.5 × ULN.~5. For females of childbearing potential, a negative pregnancy test must be documented prior to randomization.~6. Female and male patients who are fertile must agree to use an effective form of contraception with their sexual partners from randomization through 4 months after the end of treatment.~7. Signed written informed consent according to ICH/EU/GCP and national local laws.~Exclusion Criteria:~1. WHO performance status ≤ 50% (Karnofsky) or ≥ 3 (ECOG).~2. Active HBV or HCV hepatitis, or AST/ALT ≥ 2.5 x ULN and bilirubin ≥ 1.5 x ULN.~3. History of acute pancreatitis within 1 year of study or history of chronic pancreatitis.~4. History of alcohol abuse.~5. Ongoing or active infections.~6. Uncontrolled hypertriglyceridemia (triglycerides \>450 mg/dL).~7. Clinically significant, uncontrolled, or active cardiovascular disease, specifically including, but not restricted to:~   * any history of myocardial infarction, stroke, or revascularization~  * unstable angina or transient ischemic attack within 6 months prior to enrollment~  * congestive heart failure within 6 months prior to enrollment, or left ventricular ejection fraction (LVEF) less than lower limit of normal per local institutional standards within 6 months prior to enrollment~  * history of clinically significant (as determined by the treating physician) atrial arrhythmia~  * any history of ventricular arrhythmia~  * any history of venous thromboembolism including deep venous thrombosis or pulmonary embolism .~8. Uncontrolled hypertension (diastolic blood pressure \>90 mm Hg; systolic \>140 mm Hg). Patients with hypertension should be under treatment on study entry to effect blood pressure control.~9. Taking medications that are known to be associated with Torsades de Pointes.~10. Taking any medications or herbal supplements that are known to be strong inhibitors of CYP3A4 within at least 14 days before the first dose of ponatinib.~11. Creatinine level \> 2.5mg/dl or Glomerular Filtration Rate (GFR) \< 20 ml/min or proteinuria \> 3.5 g/day.~12. Impairment of gastrointestinal (GI) function, or a GI disease that may significantly alter the absorption of study drugs (e.g. rare hereditary problems of galactose intolerance , the Lapp lactase deficiency or glucose-galactose malabsorption, severe malabsorption syndrome, or extended small bowel resection).~13. Patients who are currently receiving treatment with any of the medications listed in Appendix E if the medications cannot be either discontinued or switched to a different medication prior to starting study drug. The medications listed in Appendix E have the potential to prolong QT.~14. Patients who have received any investigational drug ≤ 4 weeks.~15. Patients who have undergone major surgery ≤ 2 weeks prior to starting study drug or who have not recovered from side effects of such therapy.~16. Patients who are pregnant or breast feeding and adults of reproductive potential not employing an effective method of birth control (women of childbearing potential must have a negative serum pregnancy test within 48 hrs prior to administration of Ponatinib). Post menopausal women must be amenorrhoeic for at least 12 months to be considered of non-childbearing potential. Male and female patients must agree to employ an effective barrier method of birth control throughout the study and for up to 4 months following discontinuation of study drugs.~17. Patients with a history of another primary malignancy that is currently clinically significant or currently requires active intervention.~18. Patients unwilling or unable to comply with the protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ponatinib (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).